Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

285581

Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug Administration (FDA). The trial (NCT04669028), to be conducted at about 30 clinical U.S. sites, will be looking to recruit up to 316 people with mild to moderate Alzheimer’s. The process has not yet started, but NeurMedix expects to enroll the first patient in May. Contact information…

You must be logged in to read/download the full post.